Two whistleblowers at a pharmaceutical company responsible for one of the largest drug price increases in US history said the company bribed doctors and their staffs to increase sales, according to newly unsealed documents in federal court.
The Justice Department has now intervened in the case after conducting its own extensive investigation a sign that the government believes the allegations levied by the whistleblowers are credible. In a statement to CNN, Mallinckrodt did not deny the accusations but said the fault lies primarily with Questcor.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
UK Competition Watchdog Probes Into OCS’s £3.1 Billion Mitie Deal
Nov 18, 2026 by
CPI
Booking to Challenge EU Court Ruling Blocking $1.79B Etraveli Deal
Nov 18, 2026 by
CPI
Newsmax Sues to Block Fox-Roku Integration After $22 Billion Deal
Nov 18, 2026 by
CPI
Tesla, Hertz and Uber Face Antitrust Suit Over $4.2B Electric-Vehicle Deal
Nov 18, 2026 by
CPI
Simpson Thacher Adds Five Partners to Litigation Practice
Nov 18, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Data Portability
Nov 12, 2026 by
CPI
Mandating Access to a Dominant Platform’s Inferred Data: A Two Scenario Diagnosis
Nov 12, 2026 by
Sean Ennis
Data Portability Between Individual Control and Data Sharing at Scale
Nov 12, 2026 by
Jasper van den Boom & Inge Graef
Information Also Wants to Be Expensive: Data Portability and the Open-Systems Creed
Nov 12, 2026 by
Justin (Gus) Hurwitz
Data Portability’s Cybersecurity Paradox: When Protecting Consumer Data Restricts Competition
Nov 12, 2026 by
Sasha Hondagneu-Messner